RxDoctor Payments Data

Jessica Gonzales

Family · Houston, TXNPI 1013407535

Payments from drug & device makers

$1,455in general payments, 2019–2025

Across 58 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$230
  • Novo Nordisk$213
  • AbbVie$181
  • AstraZeneca$176
  • Gilead$123
  • Nestle Healthcare Nutrition Inc.$61
  • plus $473 from 14 others

What the payments were for

  • Food & beverage$1,455100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,455 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$26,425
Medicare patients
201
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$14,282
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,537
Albuterol Sulfate HfaAlbuterol Sulfate83$1,509
Fluticasone Propionate83$958
Atorvastatin Calcium117$750
Omeprazole35$444
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav46$408
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$372
Azelastine Hcl13$354
Methylprednisolone60$349
Gabapentin21$310
Ezetimibe12$284
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$279
Omega-3 Acid Ethyl Esters12$274
Amlodipine Besylate39$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$47$12,53717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →